Sign in

CIK 0000730272

  • Large accelerated filer

REPLIGEN CORP

Sign in to watch
Ticker
RGEN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
042729386
Phone
+1 781-449-9560
Business address
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
  1. 4 Open-market sale Director sold 26,736 shares at an average $95.27 ($2,547,035)
  2. 4 Open-market sale Director sold 1,000 shares at $91.48 ($91,480)
  3. 4 Open-market sale Chief Financial Officer sold 1,655 shares at an average $89.58 ($148,247)
  4. 4 Open-market sale Director sold 7,021 shares at an average $87.84 ($616,708)
  5. 4 Open-market sale Senior VP, R&D sold 3,005 shares at an average $90.40 ($271,645)
  6. 4 Open-market sale Director sold 10,000 shares at $93.39 ($933,900)
  7. 4 Open-market sale Chief Executive Officer sold 14,490 shares at an average $89.84 ($1,301,793)
  8. 4 Derivatives Options or other derivatives
  9. 3 Insider Initial Statement of Ownership
  10. 4 Grant or award Chief Financial Officer acquired 4,686 shares (grant or award)
  11. 4 Grant or award Chief Executive Officer acquired 18,583 shares (grant or award)
  12. 4 Grant or award Senior VP, R&D acquired 3,216 shares (grant or award)
  13. 4 Open-market sale Chief Executive Officer sold 15,210 shares at an average $90.41 ($1,375,074)
  14. 4 Open-market sale Chief Financial Officer sold 1,100 shares at an average $86.22 ($94,837)
  15. 4 Open-market sale Senior VP, R&D sold 195 shares at $86.60 ($16,887)
  16. 4 Open-market sale Director sold 4,455 shares at an average $92.81 ($413,455)
  17. 4 Open-market sale Director sold 4,000 shares at an average $98.70 ($394,793)
  18. 4 Shares withheld for taxes Senior VP, R&D gave up 295 shares (to pay taxes)
  19. 4 Exercise or conversion Chief Financial Officer acquired 3,957 shares (option exercise)
  20. 4 Open-market sale Chief Executive Officer sold 3,600 shares at an average $82.89 ($298,390)

Page 15 of 34 · 669 filings